ASH 2025: Shorter azacitidine regimen safely improves outcomes in lower-risk MDS patients
Azacitidine is a type of targeted therapy known as a hypomethylating agent, commonly used in treating myelodysplastic syndromes (MDS)
Five-day azacitidine showed superior survival outcomes and disease control in lower-risk MDS patients
All trial regimens evaluated were safe, but the five-day regimen offered the best balance of safety and efficacy
ORLANDO, DECEMBER 7, 2025 – Patients with lower-risk...
ASH 2025: Results show long-lasting benefits of CAR T cell therapy for hard-to-treat lymphoma
Lisocabtagene maraleucel (liso-cel), a CAR T cell therapy, achieved an overall response rate of 97% in the TRANSCEND FL study
Durable...
ASH 2025: New MD Anderson-developed antibody boosts immune response against blood cancers and solid cancers
New investigational therapy 77A is an antibody that converts a cancer survival protein (HSP70) into an immune system trigger
Targeting...
ASH 2025: CAR T cell therapy shows promising Phase II trial results in multiple myeloma
Anito-cel is an experimental CAR T cell therapy for relapsed/refractory multiple myeloma patients
In updated Phase II trial results, anito-cel demonstrated an overall response rate of 97% and a complete response rate of 68%
Several therapies are available in this space. Anito-cel offers robust efficacy together with a reassuringly favorable safety profile, making it an important addition to current CAR T options
Researchers identify target to overcome treatment resistance in preclinical models of KRAS-mutant cancers
Researchers identified that RASH3D19 creates a positive feedback loop that drives hyperactivity of RAS signaling and leads to tumor growth and...
Study provides comprehensive insights into DNA language models
Researchers examined five AI models on multiple genomic tasks to see how well they performed
Models performed well overall, with each having...